We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions.
- Authors
Endo, Yuki; Akatsuka, Jun; Takeda, Hayato; Hasegawa, Hiroya; Yanagi, Masato; Toyama, Yuka; Mikami, Hikaru; Shibasaki, Mikio; Kimura, Go; Kondo, Yukihiro
- Abstract
This study presents the enfortumab vedotin (EV) treatment analysis at our institution. We retrospectively analyzed patients with metastatic urothelial cancer (mUC) treated with EV between January 2021 and October 2023. EV was administered at 1.25 mg/kg on days 1, 8, and 15 in a 28-day cycle. Whole-body computed tomography scans were performed to assess the treatment response. Patient characteristics, treatment histories, response rates, progression-free survival, and adverse events were evaluated. Response rates were determined, and adverse events were recorded. Among the 20 patients, 70% were male and 65% had bladder tumors. Most patients had lung (65%) or lymph node (65%) metastases. The median follow-up was 11.2 months, with 45% of the patients succumbing to the disease. The overall response rate was 55%. The median progression-free and median overall survivals were 10.5 and 12.9 months, respectively. Severe adverse events occurred in 35% of patients. In this real-world study, EV demonstrated promising efficacy and manageable safety profiles in Japanese patients with mUC. The study's results were consistent with previous clinical trials, although a longer follow-up was required. Our findings support EV use as a treatment option for patients with mUC who exhibit disease progression after platinum-based chemotherapy and immune-checkpoint inhibitor therapy.
- Subjects
JAPANESE people; TRANSITIONAL cell carcinoma; IMMUNE checkpoint inhibitors; BLADDER cancer; PROGRESSION-free survival; COMPUTED tomography
- Publication
Current Oncology, 2024, Vol 31, Issue 2, p759
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol31020056